CobiCure Grant Accelerates the First of its Kind Non-Surgical Heart Valve for Young Children With Congenital Heart Disease, Filling a Long-Standing Gap in Pediatric MedTech
The strategic support, resources, and funding provided by CobiCure MedTech will be used to further advance the development of PolyVascular's novel polymer heart valve towards becoming the first of its kind to demonstrate human clinical readiness.
- The strategic support, resources, and funding provided by CobiCure MedTech will be used to further advance the development of PolyVascular's novel polymer heart valve towards becoming the first of its kind to demonstrate human clinical readiness.
- "CobiCure's mission, strategic ecosystem, and critical resources are a perfect match for helping PolyVascular realize their goal of eliminating invasive surgeries in children with congenital heart disease," said Emma Moran, PhD, Director of Strategy & Development at CobiCure MedTech.
- CobiCure MedTech provides an expedited pathway to sustainable commercialization that is often out of reach for many pediatric innovators and their medical devices.
- CobiCure MedTech is reimagining the pediatric medical device landscape to ensure that pediatric medicine has access to tools and technology that can transform the industry and positively impact children's lives.